Overview

A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with BGC20-0134.
Phase:
Phase 2
Details
Lead Sponsor:
BTG International Inc.